The Human Contraceptive Antibody Targets A Semenogelin Galectin-3 N-Linked Glycan Complex on the Sperm Surface
- 1Boston University Chobanian & Avedisian School of Medicine
Abstract
The human contraception antibody (HCA) is a non-hormonal topical contraceptive entering Phase II clinical trials that functions by agglutinating and immobilizing sperm. To date, the HCA epitope has been described as an N-linked polylactosamine glycan motif on CD52, but this assignment has been inferred only by colocalization with anti-CD52 and S19 antibodies in western blots. Here, we report that HCA may instead bind semenogelin-galectin-3 complexes associated with the sperm surface. Semenogelins are gel forming, highly glycosylated proteins, with molecular weights of 50-70 kDa that are cleaved into smaller segments that adhere to sperm during semen liquefaction. In this study, we isolated the HCA antigen from seminal plasma and sperm using an HCA affinity column and identified semenogelin by mass spectrometry. Western blot analysis of seminal plasma showed that HCA binds to a large smear of proteins with a higher apparent molecular mass than CD52, and that these may correspond to semenogelin sequences. Flow cytometric analysis of enzymatically deglycosylated sperm demonstrated that HCA binding requires sperm surface N-linked glycans. However, despite this apparent glycan dependence, HCA failed to bind any glycans represented on a comprehensive glycan microarray. In addition to semenogelin, Galectin-3 was identified in the HCA purified sperm lysates, supporting a model in which HCA recognizes semenogelin-derived glycopeptides that are tethered to the sperm surface via a galectin mediated interaction with an N-linked glycan. We found that O-linked glycan modifications on the semenogelin proteins contain LacNAc motifs that can bind to galectins. Finally, we found that depletion of galectins bound to the sperm surface by competitive inhibitors reduced HCA-mediated agglutination, and this could be rescued by addition of recombinant galectin-3/semenogelin-2 complexes to sperm cultures. Collectively, our findings suggest that HCA's binding site involves a semenogelin-galectin-3 complex anchored to the sperm surface via an N-linked glycan.
Related
- RNA evidence supports clinical stage antibody drug targets in oncology
- Optimal Maturation Protocols for High-Affinity Antibody Targets: A Path-Integral Approach
- A fibril-selective single-domain antibody targets pathogenic amyloid-β assemblies and protects human neurons
- IgG coating of Lactobacillus crispatus is associated with cervicovaginal immune homeostasis and reduced preterm birth rates, identifying S-layer proteins as candidate antibody targets
- 211 A discovery-to-therapeutics platform for functional antibody targeting of complex membrane-embedded tumor antigens: validation with claudin family members
BibTeX
@misc{dohadwala2026human,
title = {{The Human Contraceptive Antibody Targets A Semenogelin Galectin-3 N-Linked Glycan Complex on the Sperm Surface}},
author = {S. Dohadwala and C. Xia and S. Finn and P. Shah and S.-C. Wu and H. M. Jan and J. A. Politch and K. J. Whaley and S. R. Stowell and S. A. Malaker and C. E. Costello and D. J. Anderson},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.13.757762},
url = {https://www.biorxiv.org/content/10.64898/2026.10.13.757762v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - The Human Contraceptive Antibody Targets A Semenogelin Galectin-3 N-Linked Glycan Complex on the Sperm Surface
AU - S. Dohadwala
AU - C. Xia
AU - S. Finn
AU - P. Shah
AU - S.-C. Wu
AU - H. M. Jan
AU - J. A. Politch
AU - K. J. Whaley
AU - S. R. Stowell
AU - S. A. Malaker
AU - C. E. Costello
AU - D. J. Anderson
PY - 2026
DA - 2026/10/13
PB - bioRxiv
DO - 10.64898/2026.10.13.757762
UR - https://www.biorxiv.org/content/10.64898/2026.10.13.757762v1
AB - The human contraception antibody (HCA) is a non-hormonal topical contraceptive entering Phase II clinical trials that functions by agglutinating and immobilizing sperm. To date, the HCA epitope has been described as an N-linked polylactosamine glycan motif on CD52, but this assignment has been inferred only by colocalization with anti-CD52 and S19 antibodies in western blots. Here, we report that HCA may instead bind semenogelin-galectin-3 complexes associated with the sperm surface. Semenogelins are gel forming, highly glycosylated proteins, with molecular weights of 50-70 kDa that are cleaved into smaller segments that adhere to sperm during semen liquefaction. In this study, we isolated the HCA antigen from seminal plasma and sperm using an HCA affinity column and identified semenogelin by mass spectrometry. Western blot analysis of seminal plasma showed that HCA binds to a large smear of proteins with a higher apparent molecular mass than CD52, and that these may correspond to semenogelin sequences. Flow cytometric analysis of enzymatically deglycosylated sperm demonstrated that HCA binding requires sperm surface N-linked glycans. However, despite this apparent glycan dependence, HCA failed to bind any glycans represented on a comprehensive glycan microarray. In addition to semenogelin, Galectin-3 was identified in the HCA purified sperm lysates, supporting a model in which HCA recognizes semenogelin-derived glycopeptides that are tethered to the sperm surface via a galectin mediated interaction with an N-linked glycan. We found that O-linked glycan modifications on the semenogelin proteins contain LacNAc motifs that can bind to galectins. Finally, we found that depletion of galectins bound to the sperm surface by competitive inhibitors reduced HCA-mediated agglutination, and this could be rescued by addition of recombinant galectin-3/semenogelin-2 complexes to sperm cultures. Collectively, our findings suggest that HCA's binding site involves a semenogelin-galectin-3 complex anchored to the sperm surface via an N-linked glycan.
ER -